Chemical chaperones correct the mutant phenotype of the Delta F508 cystic fibrosis transmembrane conductance regulator protein

被引:0
|
作者
Brown, CR
HongBrown, LQ
Biwersi, J
Verkman, AS
Welch, WJ
机构
[1] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143
[3] UNIV CALIF SAN FRANCISCO,SCH MED,CYST FIBROSIS RES CTR,SAN FRANCISCO,CA 94143
来源
CELL STRESS & CHAPERONES | 1996年 / 1卷 / 02期
关键词
D O I
10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mutations in the cystic fibrosis transmembrane conductance regulator protein (CFTR) often result in a failure of the protein to be properly processed at the level of the endoplasmic reticulum (ER) and subsequently transported to the plasma membrane. The folding defect associated with the most common CFTR mutation (Delta F508) has been shown to be temperature sensitive. Incubation of cells expressing Delta F508 CFTR at lower growth temperatures results in the proper processing of a portion of the mutant CFTR protein. Under these conditions, the mutant protein can move to the plasma membrane where it functions, similar to the wild-type protein, in mediating chloride transport. We set out to identify other methods, which like temperature treatment, would rescue the folding defect associated with the Delta F508 CFTR mutation. Here we show that treatment of cells expressing the Delta F508 mutant with a number of low molecular weight compounds, all known to stabilize proteins in their native conformation, results in the correct processing of the mutant CFTR protein and its deposition at the plasma membrane. Such compounds included the cellular osmolytes glycerol and trimethylamine N-oxide, as well as deuterated water. Treatment of the Delta F508 CFTR-expressing cells with any one of these compounds, which we now refer to as 'chemical chaperones', restored the ability of the mutant cells to exhibit forskolin-dependent chloride transport, similar to that observed for the cells expressing the wild-type CFTR protein. We suggest that the use of 'chemical chaperones' may prove to be effective for the treatment of cystic fibrosis, as well as other genetic diseases whose underlying basis involves defective protein folding and/or a failure in normal protein trafficking events.
引用
收藏
页码:117 / 125
页数:9
相关论文
共 50 条
  • [1] In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant Delta F508 in murine nasal epithelium
    Kelley, TJ
    Thomas, K
    Milgram, LJH
    Drumm, ML
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) : 2604 - 2608
  • [2] Activation of endogenous Delta F508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition
    Kelley, TJ
    AlNakkash, L
    Cotton, CU
    Drumm, ML
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (02): : 513 - 520
  • [3] Airway hyperresponsiveness in FVB/N delta F508 cystic fibrosis transmembrane conductance regulator mice
    Bazett, Mark
    Haston, Christina K.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2014, 13 (04) : 378 - 383
  • [4] The ΔF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator
    Chen, EY
    Bartlett, MC
    Loo, TW
    Clarke, DM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (38) : 39620 - 39627
  • [5] Activation of the Cystic Fibrosis Transmembrane Conductance Regulator by the Flavonoid Quercetin Potential Use as a Biomarker of ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator Rescue
    Pyle, Louise C.
    Fulton, Jennifer C.
    Sloane, Peter A.
    Backer, Kyle
    Mazur, Marina
    Prasain, Jeevan
    Barnes, Stephen
    Clancy, J. P.
    Rowe, Steven M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2010, 43 (05) : 607 - 616
  • [6] Cystic Fibrosis Transmembrane Conductance Regulator ΔF508 Heterozygosity: A Spectrum of Disease Burden
    Banipal, J.
    Icard, B. L.
    Sweet, J. M.
    Loschner, A. L.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [7] Constrained bithiazoles as correctors for the ΔF508 cystic fibrosis transmembrane conductance regulator gene
    Coffman, Keith C.
    Nguyen, Huy H.
    Phuan, Puay-Wah
    Yu, Gui J.
    Bagdasarian, Alex L.
    Montgomery, Deanna
    Lodewyk, Michael W.
    Yang, Baoxue
    Yoo, Choong L.
    Verkman, Alan S.
    Tantillo, Dean J.
    Kurth, Mark J.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [8] Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients
    Dray-Charier, N
    Paul, A
    Scoazec, JY
    Veissière, D
    Mergey, M
    Capeau, J
    Soubrane, O
    Housset, C
    [J]. HEPATOLOGY, 1999, 29 (06) : 1624 - 1634
  • [9] Enhanced cell-surface stability of rescued ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones
    Varga, Karoly
    Goldstein, Rebecca F.
    Jurkuvenaite, Asta
    Chen, Lan
    Matalon, Sadis
    Sorscher, Eric J.
    Bebok, Zsuzsa
    Collawn, James F.
    [J]. BIOCHEMICAL JOURNAL, 2008, 410 (555-564) : 555 - 564
  • [10] Epithelial IgG and its relationship to the loss of F508 in the common mutant form of the cystic fibrosis transmembrane conductance regulator
    Treharne, Kate J.
    Cassidy, Diane
    Goddard, Catharine
    Colledge, William H.
    Cassidy, Andrew
    Mehta, Anil
    [J]. FEBS LETTERS, 2009, 583 (15): : 2493 - 2499